3-[4-[[3,5-Bis(trimethylsilyl)benzoyl]amino]-2-fluoro-phenyl]-2-methylpropanoic acid | 1142292-69-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[4-[[3,5-Bis(trimethylsilyl)benzoyl]amino]-2-fluoro-phenyl]-2-methylpropanoic acid
• 英文别名: 3-[4-[[3,5-bis(trimethylsilyl)benzoyl]amino]-2-fluorophenyl]-2-methylpropanoic acid
• CAS: 1142292-69-0
• 化学式: C₂₃H₃₂FNO₃Si₂
• 分子量: 445.681
• InChiKey: YOSLLHWFZSYUCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.43
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (E)-3-[4-[[3,5-bis(trimethylsilyl)benzoyl]amino]-2-fluorophenyl]-2-methylacrylic acid 在 palladium 10% on activated carbon 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 6.0h， 以94%的产率得到3-[4-[[3,5-Bis(trimethylsilyl)benzoyl]amino]-2-fluoro-phenyl]-2-methylpropanoic acid
  参考文献：
  名称：

  EP2202235

  摘要：

  公开号：

文献信息

• Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：US07855300B2

  公开（公告）日：2010-12-21

  The present invention provides a compound that exhibits an excellent antitumor effect and reduces side effects, such as skin disorders, of the existing retinoid by selectively activating on the nuclear receptor RARα, thereby possibly producing significant improvement of clinical profits. Specifically, the present invention provides a bis(trimethylsilyl)phenyl compound represented by Formula (I): wherein X is N or CH; Y is O or S; R1, R2, and R3 are the same or different and are hydrogen or lower alkyl; R4 and R5 are the same or different and are hydrogen, lower alkyl, or halogen; and a bond between a carbon atom to which R1 is attached and a carbon atom to which R2 is attached is a single bond or a double bond; or a salt thereof.

  本发明提供了一种化合物，其表现出优异的抗肿瘤效果并减少现有维甲酸类药物的副作用，例如皮肤疾病，通过选择性激活核受体RARα，因此可能产生显著的临床利润改善。具体而言，本发明提供一种由式(I)表示的双(三甲基硅基)苯基化合物：其中X为N或CH；Y为O或S；R1、R2和R3相同或不同，为氢或低碳基；R4和R5相同或不同，为氢、低碳基或卤素；以及连接R1所附着的碳原子和R2所附着的碳原子之间的键为单键或双键；或其盐。
• BIS(TRIMETHYLSILYL)PHENYL COMPOUND OR SALT THEREOF, AND USE THEREOF
  申请人：Suda Yoshimitsu

  公开号：US20100210591A1

  公开（公告）日：2010-08-19

  The present invention provides a compound that exhibits an excellent antitumor effect and reduces side effects, such as skin disorders, of the existing retinoid by selectively activating on the nuclear receptor RARα, thereby possibly producing significant improvement of clinical profits. Specifically, the present invention provides a bis(trimethylsilyl)phenyl compound represented by Formula (I): wherein X is N or CH; Y is O or S; R1, R2, and R3 are the same or different and are hydrogen or lower alkyl; R4 and R5 are the same or different and are hydrogen, lower alkyl, or halogen; and a bond between a carbon atom to which R1 is attached and a carbon atom to which R2 is attached is a single bond or a double bond; or a salt thereof.

  本发明提供了一种化合物，该化合物通过选择性激活核受体RARα，展现出优异的抗肿瘤效果并减少现有维甲酸类药物的副作用，如皮肤疾病，从而可能显著提高临床效益。具体而言，本发明提供了一种由式（I）表示的双（三甲基硅基）苯基化合物：其中X是N或CH；Y是O或S；R1、R2和R3相同或不同，是氢或低碳基；R4和R5相同或不同，是氢、低碳基或卤素；以及连接R1和R2所连接的碳原子之间的键是单键或双键；或其盐。
• EP2202235
  申请人：——

  公开号：——

  公开（公告）日：——